5 Nov. 2020 The policy brief provides a concise summary of information and considerations to ensure optimal management of influenza during the COVID-19 pandemic. It includes a list of technical guidance and other resources to assist policy makers with monitoring the situation, preventing seasonal influenza, reducing severe complications and mortality, protecting specific populations and communicating to and engaging with the public

This third edition of the landscape analysis provides regional and country-specific data. This report illustrates the complexities in surveillance of influenza and other respiratory viruses and highlights differences in the countries’ preparedness capacities through charts, infographics, tables, and brief narratives

The DCPs are a series of disease specific datasheets that list the critical commodities and the technical specifications for each commodity per disease. The DCPs inform Member States and operational partners of commodity requirements and potential gaps in the health emergency supply chain. From an operational readiness perspective, the DCPs provide the basis for a globalized stockpile system, response planning, technical guidance and supply market assessments. Initially, the DCPs consist of 11 infectious diseases; Ebola virus, Marburg virus, cholera, Lassa fever, pandemic influenza, MERS-COV, SARS, meningococcal meningitis, yellow fever, Shigellosis, and typhoid fever

revised version December 2020

Обновленная версия Декабрь 2020 г.

Auf dieser Webseite können Sie alle Pandemieplände Bundesländer herunterladen

The goal of the strategy is to prevent seasonal influenza, control the spread of influenza from animals to humans, and prepare for the next influenza pandemic. The new strategy is the most comprehensive and far-reaching that WHO has ever developed for influenza. It outlines a path to protect populations every year and helps prepare for a pandemic through strengthening routine programmes

It is recommended that egg based quadrivalent vaccines for use in the 2019-2020 northern hemisphere influenza season contain the following: an A/Brisbane/02/2018 (H1N1)pdm09-like virus; an A(H3N2) virus to be announced on 21 March 2019*; a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage); and a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage). It is recommended that the influenza B virus component of trivalent vaccines for use in the 2019-2020 northern hemisphere influenza season be a B/Colorado/06/2017-like virus of the B/Victoria/2/87-lineage. * In light of recent changes in the proportions of genetically and antigenically diverse A(H3N2) viruses, the recommendation for the A(H3N2) component has been postponed.